Study of Degenerescence CSF Hallmarks in Older Bipolar Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Bipolar Disorder
- Sponsor
- University Hospital, Grenoble
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Profile 4 neurodegeneration's biomarkers of Alzheimer's disease dosed in cerebrospinal fluid of aged subjects with bipolar disorder : Total Tau proteins, phosphorylated Tau proteins, Aß40 and Aß1-42 concentration
- Last Updated
- 7 years ago
Overview
Brief Summary
Analysis of 4 CSF Alzheimer's disease biomarkers (total and phosphorylated tau protein, Aß40 and Aß1-42) and morphological brain MRI in older patients (>60 year's old) with bipolar disorder, after an evaluation of their cognitive functions.
Comparison between two groups of patients : patients with cognitive disorders and patients without cognitive disorders.
The objective is to describe and compare the profile of those biomarkers in those two populations.
Detailed Description
Describe the profile of the 4 neurodegeneration's biomarkers of Alzheimer's disease dosed in the cerebrospinal fluid (Total Tau proteins, phosphorylated, Aß40 and Aß1-42) for old subjects suffering from bipolar disorder with or without cognitive impairment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •male or female between 60 and 80
- •french-speaking, reading and writing patient
- •affiliation to the French Social Security
- •written informed consent obtained from the patient
- •agree to undergo a lumbar puncture
- •easy accessibility for the lumbar puncture
- •Mini Mental State Examination (MMSE) \> 20
- •bipolar patients :
- •type I or II
- •state of euthymia for at least 4 weeks
Exclusion Criteria
- •at least one of the outcome measures can't be performed :
- •LP : anticoagulation, bad accessibility
Outcomes
Primary Outcomes
Profile 4 neurodegeneration's biomarkers of Alzheimer's disease dosed in cerebrospinal fluid of aged subjects with bipolar disorder : Total Tau proteins, phosphorylated Tau proteins, Aß40 and Aß1-42 concentration
Time Frame: 3 hours 50 minutes (total of the 4 primary outcome measures described)
The mean concentration of each biomarker is measured independently. The analysis between the 2 groups is done with the profile of the 4 biomarkers, not only between the profile of one biomarker to another.